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Background. While the surface of a cell normally has some amount of somatostatin receptors, these receptors are overexpressed to
averyhighdegree inmultipleneoplasticdiseases.Nodataexist foresophageal carcinoma.Purpose.To ﬁndoutwhether esophageal
carcinoma could be imaged using somatostatin receptor scintigraphy. Material and Methods. 34 patients with esophageal
lesions were prospectively examined by 99mTc-depreotide scintigraphy 2 and 4 hours after injection. Quantitative evaluation of
99mTc-depreotide uptake was performed around the lesion (T) and in healthy lung parenchyma (B) .T h er e l a t i v eu p t a k ew a s
calculated as T−B/B. Scintigraphy results were compared with histopathology from surgery or biopsy specimens from endoscopic
ultrasonography. Results.21 patients had esophageal cancer, and 13 lesions were benign. Visual assessment revealed positive 99mTc-
depreotide uptake in 16 of the 21 cancers. The 13 patients without cancer had no depreotide uptake. The Mann-Whitney U
test showed a statistically signiﬁcant diﬀerence (P<. 005) between 99mTc-depreotide uptake in malignant and benign lesions,
for both the 2-hour and the 4-hour measurements. Conclusion. Scintigraphic examination with 99mTc-depreotide is feasible for
imaging esophageal cancer, but the method is not suitable neither for screening or primary diagnosis, because of methods modest
sensitivity. Our ﬁrst results showed high speciﬁcity which should be used with caution, as the number of patients was relatively
low. Further studies are needed to determine the role of the method.
1.Introduction
In Sweden, approximately 400 patients per year are newly
diagnosed with cancer of the esophagus and an additional
200 with cancer of the cardia [1]. There are several methods
to determine this diagnosis: computed tomography (CT),
endoscopic examination of the esophagus (esophagoscopy)
combined with endoscopic ultrasonography (EUS) and
needle biopsy and positron emission tomography (PET)
examination with 18F-Fluoro-deoxyglucose (18F-FDG).
CT has the disadvantage that it is less able to diagnose
overgrowth of the tumor to adjacent organs and to detect
small tumors <1cm and growth to diﬀerent layers in
the esophageal wall. PET and the combination of 18F-
FDG-PET/CT are both more accurate than CT alone with
respect to diagnosing lymph node metastasis close to the
tumor, and therefore staging [2]. EUS is superior to 18F-
FDG-PET/CT with respect to diagnosing tumor growth
through diﬀerent layers in the esophageal wall, overgrowth
to adjacent organs, and lymph node metastasis close to
the tumor [2–5]. Examination with 18F-FDG-PET is based
on the metabolic activity of the tumor, and reﬂects its
pathophysiological characteristics. However, despite their
high sensitivity in detecting esophageal cancer [2], these
methods lack speciﬁcity; an elevated 18F-FDG uptake could
be seen in diﬀerent nonmalignant conditions, such as
inﬂammation and Barrett’s esophagus [6–12]. Another way
to characterize tumors is evaluation of diﬀerent receptors,
such as the somatostatin receptors.
While the surface of a cell usually includes some amount
of somatostatin receptors, these receptors are over-expressed
to a very high degree in multiple neoplastic diseases such as2 International Journal of Molecular Imaging
neuroendocrine tumors [13] and in tumors of the central
nervous system, breast, lung, and lymphoid tissue [12, 14].
When this study was initiated, there were several radio-
pharmaceuticals available for somatostatin receptor scintig-
raphy, including 99mTc-depreotide. This tracer is 99mTc-
labeled, and demonstrates good imaging characteristics
with a short investigation protocol. 99mTc-depreotide has
proven valuable in diagnosing pulmonary nodules [9–
11]. We have previously used scintigraphy with 99mTc-
depreotide for the diagnosis of lung cancer, and showed
an accurate discrimination between benign and malignant
lesions with conventional gamma cameras [6, 9, 11]. There
was a physiologically low 99mTc-depreotide uptake in the
thorax region. Therefore, visualization of overexpression of
somatostatinreceptorsincancertypesotherthanlungcancer
should, theoretically, be feasible. Moreover, our previous
resultsshowedthatthistraceraccumulatesbothinsquamous
cancers and in adenocarcinomas [15], which is of clinical
relevance in view of the almost exponential increase in the
incidence of adenocarcinoma in the distal esophagus.
The aim of the present study was to ﬁnd out whether
esophageal cancer can be imaged scintigraphically with
99mTc-depreotideandtodeterminetheuptakecharacteristics
of 99mTc-depreotide in the two main cancer types of the
esophagus and relate these to results in patients with benign
lesions (Barrett’s esophagus).
2.MaterialandMethods
The study was approved by the Regional Ethical Review
Board in Stockholm, Sweden and the Radiation Safety
Committee at Karolinska University Hospital, Huddinge.
2.1. Patients. 34 patients with dysphagia were referred to the
Surgery Department at Huddinge University Hospital and
further examined with gastroscopy, EUS, and CT. Nine of
these were female and 25 male, with a median age of 63-
64 years (range: 33–85 years). Among the 34 patients, 21
had cancer of the esophagus and 13 had Barrett’s esophagus.
Five of the 21 patients with esophageal cancer had a Barrett’s
esophagus too. The cancer diagnosis was established by
histopathological examination of biopsy specimens in 19
casesandwithEUSandcytologicalconﬁrmationofdiagnosis
in 2 cases. All patients with Barrett’s esophagus were
diagnosed via endoscope and subsequent multiple biopsies.
Locoregional lymph nodes were evaluated with EUS and
histological examination of surgical specimen.
2.2. Somatostatin Receptor Scintigraphy. 99mTc-depreotide
(740MBq) was administered via an antecubital vein. Single-
photon emission computed tomography (SPECT) of the
thorax was performed at 2 and 4 hours after injection, with
the arms elevated, using three diﬀerent gamma cameras.
Most of the patients (25 of 34) were examined with a
double-headed gamma camera (E-Cam, Siemens, Erlangen,
Germany) and low-energy high-resolution parallel-hole col-
limators, using a 128 × 128 matrix, 64 projections through
360◦ rotation, and an acquisition time of 40s per projection.
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Figure 1: Evaluation of scintigraphic images with 99mTc-depreo-
tide.Regionofinterest(ROI)wasdrawnmanuallyaroundtheesop-
hageal tumor on each slice, using small margins, and a background
ROI was drawn in healthy lung parenchyma.
An additional 5 patients were examined with a double-
headed gamma camera (DST-XL; Sopha Medical Vision
Scandinavia AB, Gif-sur-Yvette, France) and low-energy
ultra-high-resolution parallel-hole collimators, using the
sameacquisitionparametersasabove.Finally,4patientswere
examined with a three-headed gamma camera (Picker IRIX,
Cleveland, Ohio, USA) and low-energy high-resolution
parallel-hole collimators, using a 128 × 128 matrix, 60
projections through 360◦ rotation, and an acquisition time
o f6 4sp e rp r o j e c t i o n .T r a n s v e r s es l i c e sw e r er e c o n s t r u c t e d
with an iterative algorithm (HOSEM v 3.5 iterative program;
Hermes/NUD, Stockholm, Sweden) and formatted as a
128 × 128 matrix without attenuation correction. Images
were postﬁltered with a three-dimensional Fourier ﬁlter
(Butterworth ﬁlter) with a cut-oﬀ frequency of 1.1cycles/cm
(order 5.00).
The results were evaluated both through visual assess-
ment and through quantitative calculations in the 2-hour
and 4-hour images. CT scans were used for an accurate
localization of the 99mTc-depreotide uptake and for place-
ment of the region of interest (ROI). On visual assessment,
any focal 99mTc-depreotide uptake in the region of the
known esophageal lesion was considered pathological. The
quantitative evaluation of 99mT c - d e p r e o t i d eu p t a k ew a sp e r -
formed retrospectively on SPECT images in all 34 patients.
First, an ROI was drawn manually around the esophageal
tumoroneachslice,usingsmallmargins.Next,abackground
R O Iw a sd r a w ni nh e a l t h yl u n gp a r e n c h y m a( Figure 1). A
volume of interest (VOI) was obtained by adding all ROIs.
In-house software, originally developed for volumetric mea-
surements in magnetic resonance images and implemented
on a Hermes workstation (Hermes Medical Solution AB,
Stockholm, Sweden), was used to calculate the total counts
and volume of the tumor and background VOIs, thus givingInternational Journal of Molecular Imaging 3
a count density (counts/cm3). To produce a normalized
tumor uptake, each patient was normalized to his or her own
normal lung parenchyma using the formula U = (T − B)/B,
where U is the normalized uptake, T is the count density
in the tumor, and B is the count density in the lung pare-
nchyma. To increase accuracy and to investigate the intraob-
server variability, evaluations were performed twice, 6 mon-
ths apart, by the same radiologist and the mean value of the
two uptake values was used in further analysis. In addition,
a second radiologist made individual evaluations in order to
investigate the interobserver variability of the uptake values
at 2-hour images.
2.3. Statistics. For patients with negative uptake (i.e., tumor
count density lower than the lung background count den-
sity), the uptake was scored as zero. Due to the small number
ofpatientsineachgroup,anonparametrictestwaschosen.A
two-sided Mann-Whitney U test was used to investigate the
diﬀerence in uptake between malign and benign tumors. To
assess intraobserver and interobserver variability, intraclass
correlation coeﬃcients (ICC) were determined [16]. All
statistical analysis was performed in Statistica 9.0 (StatSoft.
Inc, Tulsa, OK, USA). Data were analyzed based on both
the 2-hour and the 4-hour postinjection recordings except
for the ICC which was only determined for the 2-hour
recordings. A diﬀerence in uptake was considered signiﬁcant
if the P value was less than .05.
3. Results
Among the 21 patients with cancer of the esophagus, 8 had
squamous cell carcinoma, 11 had adenocarcinoma, 1 had an
undiﬀerentiated cancer, and 1 had an intramucosal cancer.
Tumor size varied from 5mm to 11cm. The position of
the tumor was in the proximal esophagus in 2 cases, in the
middle part in 5 cases, and in the distal part in the remaining
14 cases.
Visual assessment revealed a pathological 99mTc-depreo-
tide uptake in 16 of the 21 cancer patients (true-positive
76%)andanabsenceofpathologicaluptakeintheremaining
5 (false-negative 24%). Six of the eight patients with
squamouscellcarcinomaandnineoftheelevenpatientswith
adenocarcinoma showed a pathological 99mTc-depreotide
uptake. The remaining patient with pathological uptake
had an 11cm undiﬀerentiated cancer in the mid-esophagus
with a very high 99mTc-depreotide uptake. Among the false-
negative cases, one had a small (5mm) squamous cell cancer
located in the middle part of the esophagus. The remaining
four undetectable cancers were above 1cm in size (varying
from 12 × 9mmto12 × 38mm) and were located in the
distal part of the esophagus. The details of all recordings
are given in Table 1. The sensitivity of 99mTc-depreotide
scintigraphy in the detection of esophageal cancer was thus
0.76 95% conﬁdence interval 0.55 to 0.89.
There was no 99mTc-depreotide uptake in the columnar
metaplastic mucosa in any of the 13 Barrett’s patients,
irrespective of the presence of low and high-grade dysplasia
in the metaplastic epithelium (Figure 2). The speciﬁcity of
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Figure 2: 99mTc-depreotideuptakemeasured2hoursafterinjection
in patients with esophageal cancer and Barrett’s esophagus.
99mTc-depreotide scintigraphy in this cohort of patients was
thus 1.00, 95% conﬁdence interval 0.77 to 1.00.
There were no signiﬁcant diﬀerences between the
ROI delineation and quantitative measurement of 99mTc-
depreotide performed on the 2-hour acquisitions and those
performed on the 4-hour acquisitions. A corresponding
second ROI delineation and quantiﬁcation, performed 6
months later, gave consistent results. Both intraobserver
and interobserver variability was low with ICC = 0.97
when comparing the evalutions by the same radiologist
(intraobserver) and ICC = 0.96 when comparing the evalua-
tions made by the two radiologists (interobserver).
A statistically signiﬁcant diﬀerence (P<. 005) was found
between 99mTc-depreotide uptake in malignant lesions com-
pared to that in benign or premalignant lesions (Figure 2),
both 2 and 4 hours after injection. The absolute 99mTc-
depreotide uptake value was also higher in all malignant
lesions after 2 compared to 4 hours. There was no diﬀerence
in uptake between adenocarcinoma and squamous cell
carcinoma.
In the 13 patients who had lymph node metastases at the
ﬁnal examination of the surgical specimen and with EUS
only 5 showed 99mTc-depreotide uptake in the area of the
lymph nodes.
4. Discussion
In this study, we have shown that the imaging of esophageal
cancer by means of somatostatin receptor scintigraphy with
99mTc-depreotide is feasible. Our hypothesis was based
on two facts: ﬁrst, that the physiological 99mTc-depreotide
uptakeinthethoraxislow.Therefore,thiscouldbeasuitable
area for tumor detection in most cases, and, second, that
esophageal cancer has the same main histopathological types
as lung cancer such as adenocarcinoma and squamous cell4 International Journal of Molecular Imaging
Table 1: Tumor type, size, and location, CT result, and 99mTc-depreotide uptake in 21 esophageal cancer patients.
N Diagnosis Tumor size in mm Location CT 99mTc-depreotide
1 Sqcc 5 Middle Neg. Neg.
2A c 1 7 × 45 Distal Pos. Pos.
3S q c c 5 5 × 40 proximal Pos. Pos.
4A c i n B . 6 5 × 55 × 13 Distal Pos. Pos.
5A c 9 0 × 75 × 25 Distal Pos. Pos.
6I m c a n d B . 1 2 × 9 Distal Neg. Neg.
7S q c c 3 0 × 10 Middle Pos Pos
8A c 2 0 × 90 Middle Pos. Pos.
9A c 6 0 × 25 × 9 Distal Pos. Pos.
10 Sqcc 50 × 45 Distal Pos. Pos.
11 Small cell cancer 110 × 24 Middle Pos. Pos.
12 Ac in B 60 × 65 Distal Pos. Pos.
13 Ac 25 × 15 Distal Neg. Pos.
14 Ac in B 20 × 25 Distal Pos. Pos.
15 Sqcc 60 × 10 proximal Pos. Pos.
16 Sqcc 15 × 55 Distal Pos. Pos.
17 Ac 15 × 50 Distal Pos. Pos.
18 Ac 15 × 15 Distal Neg. Neg.
19 Ac in B 20 × 25 Distal Neg. Neg.
20 Sqcc 14 × 5 Middle Neg. Pos.
21 Sqcc 23 × 38 × 12 Distal Pos. Neg.
Ac: adenocarcinoma; Sqcc: squamous cell carcinoma; B: Barrett’s esophagus; Imc: intramucosal cancer. 99mTc-depreotide uptake classiﬁed as negative or
positive based on visual assessment. CT pos.: tumor is visible on the CT images; CT neg.: tumor is not visible on the CT images.
carcinoma. As scintigraphy with 99mTc-depreotide is useful
for lung cancer detection, this second fact suggested that it
could also be applied in esophageal cancer.
The majority of tumors (16/21) displayed a signiﬁcant
uptake of the tracer which could be clearly distinguished
from that in the surrounding tissue. It was not unexpected
that tumors under or near 10mm in size were missed on
the scintigraphic images. The detection limit of conventional
gamma camera due to poor spatial resolution is well
known,andaccordingtowidespreadconsensusscintigraphic
methods are not suitable for screening purposes for any
cancer types. Another observation is that even larger tumors
in the distal part of the esophagus, 4 of 13 in the present
study, could be missed with this method. Uptake of 99mTc-
depreotide in lung cancers located in the lowest part of the
right low lobe [6] and even in esophageal cancers located at
the level of the diaphragm and lower in the abdomen could
be obscured because of the high physiological tracer uptake
in the liver.
Our sensitivity ﬁgure of 76% is only an approximate
value, due to the small number of patients in this study. Still,
this is somewhat lower than both the sensitivity for detecting
lung cancers [2, 6–11] with the same tracer and that for
detecting lung cancer with 18F-FDG-PET [6–8]. While 18F-
FDG uptake reﬂects a metabolic activity of the lesion and is
not speciﬁc to tumors [6–8], overexpression of somatostatin
receptors on tumor cells could give another valuable piece of
information regarding tumor properties.
As a control group, we used patients with Barrett’s
esophagus. Barrett’s esophagus refers to an abnormal change
(metaplasia) in the cells in the lower end of the esophagus.
It is thought to be caused by damage from chronic acid
exposure or reﬂux oesophagitis. This metaplasia confers an
increased risk of adenocarcinoma. None of the 13 cancer-
free Barrett’s esophagus patients in this study showed an
increased 99mTc-depreotide uptake. Meanwhile, only 3 of 5
patients with both cancer and Barrett’s esophagus showed an
increased 99mTc-depreotide uptake, leaving 2 false-negative
results. The speciﬁcity of 100% for the applied method is
high but should be used with caution, as the number of
patients was relatively low and the spectra of diﬀerent benign
conditions in the esophagus was not fully represented in this
pilot study.
Our results in the detection of loco-regional lymph
node metastases were unsatisfactory. Only 5 of 13 patients
with metastases seen with EUS and conﬁrmed by histolog-
ical examination were clearly detected by 99mTc-depreotide
scintigraphy. It is probably caused by the close location to
the primary tumor, where a high depreotide uptake cannot
be separated from the uptake in the metastatic lymph nodes.
It was disappointing to note that very few of the local,
metastatic lymph nodes could be detected by this method.
Through this pilot observation it can be envisioned that this
technology cannot add to the available methods, such as
EUS, in determining the node status in oesophageal cancer
during the diagnostic and therapeutic workup.International Journal of Molecular Imaging 5
As this study is the ﬁrst of its kind, we considered it
important to explore whether the quantitative assessment
was reliable between diﬀerent investigators and over time.
Bothintraobserverandinterobservervariabilitywasverylow
meaning that the applied calculations have good reliability.
We applied a somatostatin receptor scintigraphy with
99mTc-depreotide in a previously nonexplored cancer type
where the optimal acquisition time was unknown. We used
the same starting point for the imaging session as for the
standard procedure in the detection of lung cancer, that
is, 2 hours after injection [8, 10, 11]. During the last
decade there has been a trend of performing a double-phase
registrationinordertoincreasespeciﬁcity.Thedouble-phase
registration is based on assumptions that the relative tracer
uptake in benign lesions decreases with time, while uptake
in malignant lesions remains high or even increases with
the time [10, 17–20]. This approach is now in routine for
parathyroid scintigraphy, and its use has also been suggested
for scintimammography, tumor imaging with 18F-FDG-
PET, and somatostatin receptor scintigraphy with 99mTc-
depreotide in lung cancer patients [17–20]. In order to
optimize the imaging procedure from the very beginning, we
performed double-phase registrations with imaging 2 and 4
hours after injection. Our results showed that in the majority
of patients the absolute uptake decreased more rapidly in the
background (i.e., the normal lung parenchyma compared to
the malignant lesions in the esophagus), resulting in a higher
relative uptake in cancer over time. As both the 2-hour,
andthe4-hourquantitativeevaluationsshowedastatistically
signiﬁcant diﬀerence (P<. 005) between 99mTc-depreotide
uptake in malignant lesions and in lesions without cancer,
the 4-hour imaging seems unnecessary, and thus could be
omitted for practical reasons.
Although future immunohistochemical studies will be
needed to carefully map the density, detailed distribution,
and localization of somatostatin receptors in the squamous
cell esophageal carcinoma and adenocarcinomas, our data
indicate that there is no major diﬀerence as reﬂected by the
similarity in tracer accumulation between these two major
tumor types. It is, however, of particular interest that in
patients with Barrett’s esophagus, no accumulation of tracer
wasobservedeitherinthosewithorinthosewithoutdysplas-
tic histomorphologic changes in the columnar epithelium.
Since there is no corresponding preneoplastic condition,
concerningthesquamouscellcarcinomadevelopment,itcan
be hypothesized that the somatostatin receptor expression
reaches far higher levels in inﬁltrative neoplastic growth
than in the intraepithelial neoplastic disease states. If so,
this observation may be potentially very important and oﬀer
unique clinical opportunities, for example, when PET/CT
or somatostatin receptor scintigraphy with 99mTc-depreotide
technologies are applied.
Results of this pilot study showed feasibility of imaging
oesophageal carcinoma with labeled somatostatin receptor
analogue. We used a single-photon emitting tracer, but the
results should be applicable or even better with positron
emitting tracers. Use of PET/CT cameras combines a better
spatial resolution of functional PET imaging with detailed
anatomical information leading to a higher sensitivity.
A multitude of new PET analogs are applied, whereas
[68Ga-DOTA0,T y r 3]o c t r e o t i d e[ 21]o r[ 68Ga-DOTA0,T y r 3]
octreotate [22] is likely to become the new standard for
somatostatin receptor imaging with PET. This is because
these analogs have a high aﬃnity for the somatostatin
receptor subtype-2 and because 68Ga is a generator product
with a relatively simple labeling [23]. The additional reason
is that their 90Y- or 177Lu-labeled counterparts are used for
PeptideReceptorRadionuclideTherapy(PRRT)anditseems
desirable that peptide used in diagnostic imaging mimics the
peptide used later for therapy.
Afterthesuccessfulvisualizationofsomatostatinreceptor
positive tumors, a logical next step would be to use
radiolabelled somatostatin analogues as a treatment of these
patients. Such attempts were undertaken in patients with
inoperable and/ormetastatic neuroendocrine tumors. While
the objective responses for chemotherapy with the median
time to progression is reported to be less than 18 months,
PRRT with 90Y-octreotide or 177Lu-octreotate performs
considerably better with a median time to progression of 30
and 40 months, respectively [23], and signiﬁcantly improved
quality of life [24].
What could the future clinical application of our results
be? Obviously, the method is not suitable neither for
screening or primary diagnosis, because of methods modest
sensitivity. Could this method be used for the detection of
distant metastases expressing somatostatin receptors with
somatostatin receptor-mediated radionuclide therapy as a
consequent result? Does the uptake of the 99mTc-depreotide
could be related to the prognosis of the oesophageal tumor?
Maythismethodbeusedinevaluationoftreatmentresponse
in patients with tracer uptake? Does the natural history of
Barrett’s esophagus and its malignisation could be predicted
by tracer uptake? These issues are still to be answered.
4.1. In Conclusion. Scintigraphic examination with 99mTc-
depreotide is feasible for imaging esophageal cancer, but
the method is not suitable neither for screening or primary
diagnosis, because of methods modest sensitivity. Our ﬁrst
results showed high speciﬁcity which should be used with
caution, as the number of patients was relatively low.
Acquisitions starting 2 hours after injection are optimal and
suﬃceforimaging.Furtherstudiesareneededtoexploreand
determine the role of somatostatin receptor scintigraphy in
clinical practice.
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